A notable advancement in glucose care is emerging with the approval of tirzepatide at a dosage of 45mg. This updated formulation builds upon the existing success of tirzepatide, a dual GIP and GLP-1 agonist, and https://umairmqem638212.bloginder.com/41468879/revolutionary-introduction-tirzepatide-45mg-for-diabetes-regulation